Prognostic Factors After Liver Transplantation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients who received adult liver transplantation in Changhua Christian hospital from 2002 to 2019
Exclusion Criteria:
- patients who did not have suitable donor for liver transplantation
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Liver transplant
|
liver transplantation for chronic liver disease or acute liver failure
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
number of participants with morbidity and mortality after surgery
Time Frame: upto one month after surgery
|
post-operative complications which requiring interventions, related to organ failure and hospital mortality
|
upto one month after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
long-term survival rate
Time Frame: upto 5 years after surgery
|
1,5 year survival rate
|
upto 5 years after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Yao-Li Chen, Department of General Surgery, Changhua Christian Hospital, Changhua, Taiwan
Publications and helpful links
General Publications
- Lee SG, Hwang S, Moon DB, Ahn CS, Kim KH, Sung KB, Ko GY, Park KM, Ha TY, Song GW. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl. 2008 Jul;14(7):935-45. doi: 10.1002/lt.21445.
- Chang Y, Cho Y, Lee JH, Lee YB, Cho EJ, Yu SJ, Sinn DH, Kim BH, Kim SH, Yi NJ, Lee KW, Kim JM, Park JW, Kim YJ, Yoon JH, Joh JW, Suh KS. Comparison of Models for Tumor Recurrence after Liver Transplantation for the Patients with Hepatocellular Carcinoma: A Multicenter Long-Term Follow-Up Study. Cancers (Basel). 2019 Sep 3;11(9):1295. doi: 10.3390/cancers11091295.
- Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P; Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009 Jan;10(1):35-43. doi: 10.1016/S1470-2045(08)70284-5. Epub 2008 Dec 4.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 191244
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Diseases
-
NCT07122700RecruitingLiver Fat | Cirrhosis, Liver | Liver Fibrosis | NASH | Liver Inflammation | Metabolic Associated Fatty Liver Disease | Liver Steatoses | Metabolic Associated Steatotic Liver Disease
-
NCT06111859RecruitingHepatitis | Liver Fat | NAFLD | Fibrosis, Liver | Liver Disease Chronic | Liver Steatoses | NASH With Fibrosis
-
NCT07053488RecruitingLiver Diseases | Liver Failure | Liver Cirrhosis | Liver Metastases | Liver Cancer | Liver Transplant Rejection | Liver Steatoses
-
NCT06615934Not yet recruitingLiver Transplant; Complications | Liver Transplant Disorder | End-stage Liver Disease
-
NCT04107883UnknownLiver Transplantation | End Stage Liver DIsease
-
NCT07519057RecruitingEnd Stage Liver Disease | Liver Transplantation | Liver Transplant | Liver Transplant Surgery
-
NCT07613827Enrolling by invitationLiver Steatosis | Liver Fibrosis | Liver Fibrosis Progression in Chronic Liver Disease | Steatotic Liver Disease | Steatotic Liver Disease of Mixed Origin (MetALD)
-
NCT02983669CompletedFatty Liver | Fatty Liver, Nonalcoholic
-
NCT03386890UnknownNonalcoholic Fatty Liver Disease | Liver Steatosis | Liver Fibrosis
-
NCT02719210Completed
Clinical Trials on liver transplantation
-
NCT01711957Unknown
-
NCT07383194Not yet recruitingLiving Donor Liver Transplantation
-
NCT03775863CompletedLiver Transplant Disorder | Liver Carcinoma
-
NCT06140134RecruitingIntrahepatic Cholangiocarcinoma | Cholangiocarcinoma, Intrahepatic
-
NCT07336576CompletedCongenital Biliary Dilation
-
NCT07301853RecruitingLiving Donor Liver Transplantation Recipients | Deceased Donor Liver Transplantation Recipients | Living Liver Donor
-
NCT01479608RecruitingColorectal Cancer | Liver Metastasis
-
NCT06169592RecruitingLiver Cirrhosis | Liver Transplant; Complications
-
NCT05398380RecruitingColorectal Cancer | Liver Metastases | Genetic Change
-
NCT05193253Completed